Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in gBRCA-mutated metastatic breast cancer
NCT02000622Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of olaparib in breast cancer, sponsored by AstraZeneca. Started Mar 2014; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02000622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02000622.